NCT02916771: Phase 2: Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in SMM
Active, not recruiting
Updated: Sep 27, 2022
NCT02916771: Phase 2: Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma
Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma
This research study is evaluating a new drug called "ixazomib" as a possible treatment for Smoldering Multiple Myeloma.
Sponsor
Collaborators
ClinicalTrials.gov Identifier: NCT02916771
Official Title: Phase II Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma
First Posted : September 27, 2016
Click here for details on ClinicalTrials.gov
Drug: Ixazomib
Drug: Lenalidomide
Drug: Dexamethasone
Location
United States, Massachusetts